Head-to-head evidence
Gemigliptin vs Gosogliptin
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Type 2 Diabetes
Shared mechanism: DPP-4 · full Type 2 Diabetes pipeline
Gemigliptin · Zemiglo
Developed by LG Chem
NCT01787396 · Phase 3 · completed
This was a randomized, quadruple-blind trial (n=433) with three arms: gemigliptin plus metformin, gemigliptin alone (with a matching metformin placebo), and metformin alone (with a matching gemigliptin placebo). The primary endpoint, HbA1c change at 24 weeks, favored the combination over either monotherapy.
Gosogliptin
Developed by SatRx
NCT03088670 · Phase 3 · completed
The study used randomization and an active comparator, but it was open-label and its primary endpoint was change in HbA1c, a surrogate measure rather than a hard clinical outcome. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Gemigliptin's landscape · Gosogliptin's landscape